Document Detail


Colesevelam hydrochloride: a novel bile acid-binding resin.
MedLine Citation:
PMID:  11485143     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of colesevelam hydrochloride, a bile acid-binding resin. METHODS: MEDLINE searches (1966-June 2000) and manufacturer prescribing literature were employed to find articles on colesevelam. Additional studies and abstracts were identified from the bibliographies of reviewed literature. STUDY SELECTION AND DATA EXTRACTION: All articles identified from data sources were evaluated, and all information deemed relevant was included in this review. Priority was given to randomized, double-blind, placebo-controlled studies. FINDINGS: Colesevelam HCl is a nonabsorbed hydrogel with bile acid sequestrant properties. Monotherapy using colesevelam in once-daily or two divided daily doses of 1.5-4.5 g has produced significant reductions in total cholesterol and low-density lipoprotein (LDL) cholesterol. Mean LDL cholesterol decreases to 20% have been noted when the patient is on 3.75-4.5 g/d. Increases in high-density lipoprotein (HDL) cholesterol have been observed (up to 9%), whereas triglycerides (TG) have increased significantly to 25% in some studies. In unpublished studies, combined use of colesevelam plus hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor have produced greater reductions in LDL cholesterol than either the statin or colesevelam administered alone. The efficacy of colesevelam monotherapy is slightly less than or similar to cholestyramine or colestipol in decreasing LDL cholesterol, although colesevelam is more potent on a gram-to-gram basis. Adverse effects have been minimal with colesevelam in published studies; this suggests an advantage over cholestyramine or colestipol therapy. Colesevelam appears to be more cost-effective than the packet dosage form of the brand formulation of the older bile acid resins. Care in selection of an appropriate agent should be exercised when considering the issues of adverse effects and palatability. CONCLUSIONS: Colesevelam alone or combined with an HMG-CoA reductase inhibitor is effective in the reduction of total and LDL cholesterol. Since colesevelam is formulated as a tablet, problems with palatability such as with the powder formulation of the bile acid-binding resins are likely to be eliminated.
Authors:
M A Aldridge; M K Ito
Related Documents :
7705553 - Feeding trans fatty acids to rats has no effect on the intestinal uptake of glucose, fa...
16484503 - Cholesterol dependent downregulation of mouse and human apical sodium dependent bile ac...
1242283 - Remarks on the aqueous humor/plasma ratios for amino acids and related compounds in pat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  35     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:    2001 Jul-Aug
Date Detail:
Created Date:  2001-08-03     Completed Date:  2001-12-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  898-907     Citation Subset:  IM    
Affiliation:
School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Allylamine* / adverse effects,  analogs & derivatives*,  pharmacokinetics,  therapeutic use
Anticholesteremic Agents* / adverse effects,  pharmacokinetics,  therapeutic use
Biological Availability
Carrier Proteins / pharmacology*
Cholesterol, LDL / blood
Drug Interactions
Female
Humans
Hydroxysteroid Dehydrogenases*
Hypercholesterolemia / drug therapy*
Male
Membrane Glycoproteins*
Middle Aged
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Carrier Proteins; 0/Cholesterol, LDL; 0/Membrane Glycoproteins; 0/bile acid binding proteins; 107-11-9/Allylamine; 182815-44-7/colesevelam; EC 1.1.-/Hydroxysteroid Dehydrogenases; EC 1.1.1.-/AKR1C2 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pulmonary fibrosis induced by cyclophosphamide.
Next Document:  Statin-fibrate combination therapy.